TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Quel est le ratio P/E de Transmedics Group Inc (TMDX) ?
Le ratio P/E de Transmedics Group Inc est de 129.7533
Qui est le CEO de Transmedics Group Inc ?
Dr. Waleed Hassanein est le President de Transmedics Group Inc, il a rejoint l'entreprise depuis 1998.
Quelle est la performance du prix de l'action TMDX ?
Le prix actuel de TMDX est de $105.11, il a diminué de 0.01% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Transmedics Group Inc ?
Transmedics Group Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Transmedics Group Inc ?
La capitalisation boursière actuelle de Transmedics Group Inc est de $3.5B
Est-ce que Transmedics Group Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 15 analystes ont établi des notations d'analystes pour Transmedics Group Inc, y compris 5 achat fort, 7 achat, 4 maintien, 0 vente et 5 vente forte